October 25, 2022
ASBM’s recent survey of 401 U.S. physicians was featured in the October issue of the journal Oncology Practice Management. The article discussed a poster presentation given by ASBM Chairman Ralph McKibbin, MD, FACP, FACG, AGAF at the Drug Information Association Global Annual Meeting (DIA 2022) on June 20th, in Chicago, IL. View the poster here. The survey findings consistently […]
October 20, 2022
In October, Amgen released its full 2022 Biosimilar Trends Report. The report’s findings had been previewed earlier this year by Amgen’s Global Biosimilars Commercial Lead, Chad Pettit at a June 29th webinar hosted by ASBM and GaBI Journal. View the webinar “Key Factors for Successful Uptake of Biosimilar Markets” here. Read GaBI Journal’s Meeting Report here. The full report […]
October 19, 2022
On October 19th, ASBM Advisory Board Chair Philip Schneider participated in the 7th Annual National Policy & Advocacy Summit on Biologics, The event was hosted in Washington, DC by the Biologics Prescribers Collaborative and was also streamed online. Professor Schneider appeared on the opening panel discussion entitled “The Emerging Biologics Landscape”, which also featured Chad Pettit, Executive Director […]
October 19, 2022
On October 19th, ASBM Advisory Board Chair Philip Schneider participated in the 7th Annual National Policy & Advocacy Summit on Biologics, The event was hosted in Washington, DC by the Biologics Prescribers Collaborative and was also streamed online. Professor Schneider appeared on the opening panel discussion entitled “The Emerging Biologics Landscape”, which also featured Chad Pettit, Executive Director […]
October 18, 2022
On October 18th, ASBM participated in the World Health Organization’s 75th Consultation on International Non-proprietary Names (INN) for Pharmaceutical Substances, held in Geneva, Switzerland. This was the nineteenth INN Consultation in which ASBM has participated. ASBM was represented by Executive Director Michael Reilly, Esq., and Advisory Board Chair Philip Schneider, MS, FASHP. The proceedings at […]
October 13, 2022
World Sight Day is observed worldwide every year on the second Thursday of October. This World Health Organization-designated day falls on 13 October this year. The purpose of World Sight Day is to increase public awareness about blindness, vision impairment, vision care, and ocular issues. The WHO estimates that 1 billion people worldwide suffer from […]
October 13, 2022
World Sight Day is observed worldwide every year on the second Thursday of October. This World Health Organization-designated day falls on 13 October this year. The purpose of World Sight Day is to increase public awareness about blindness, vision impairment, vision care, and ocular issues. The WHO estimates that 1 billion people worldwide suffer from […]
October 12, 2022
On October 12, ASBM Immediate Past Chair Madelaine Feldman, MD, FACR participated in a forum held by STAT, entitled “Biosimilars’ Meteoric Moment”. The forum focused on the long-awaited arrival of multiple adalimumab biosimilars in 2023 and asked experts from a variety of fields to speculate on what 2023 holds for the biosimilars market. Speakers included: Madelaine A. […]
October 10, 2022
As reported in Generics Bulletin October 10th, Dr. Sarah McMullen, India country director for the US Food and Drug Administration underscored that there’s no real distinction in the standards to determine the safety or efficacy for both biosimilars and interchangeable biosimilars, and put forth a “fact check” to dispel the general notion among patients that interchangeables are […]
October 10, 2022
As reported in Generics Bulletin October 10th, Dr. Sarah McMullen, India country director for the US Food and Drug Administration underscored that there’s no real distinction in the standards to determine the safety or efficacy for both biosimilars and interchangeable biosimilars, and put forth a “fact check” to dispel the general notion among patients that interchangeables are […]
